Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Xtant Medical Holdings ( (XTNT) ) has shared an update.
On April 13, 2026, Xtant Medical Holdings and Dilon Technologies announced an exclusive U.S. distribution agreement granting Xtant the rights to import, market and sell Dilon’s FDA-approved HEMOBLAST Bellows surgical hemostatic agent. Xtant entered the agreement on April 10, 2026, paying a $5 million exclusivity fee while Dilon continues manufacturing in France and transitions its existing U.S. customer contracts to Xtant.
As part of the deal, Xtant hired approximately 20 of Dilon’s U.S. sales personnel to support commercialization of HEMOBLAST Bellows and target the estimated $2.0 billion global market for hemostatic products. The transaction significantly expands Xtant’s product portfolio and sales reach in surgical hemostasis, and the company said it plans to update its full-year 2026 financial guidance in connection with reporting first-quarter 2026 results.
The most recent analyst rating on (XTNT) stock is a Buy with a $1.00 price target. To see the full list of analyst forecasts on Xtant Medical Holdings stock, see the XTNT Stock Forecast page.
Spark’s Take on XTNT Stock
According to Spark, TipRanks’ AI Analyst, XTNT is a Neutral.
The score is supported primarily by improving financial performance (profitability and cash flow turning positive, and leverage declining). Offsetting this, technical signals remain weak with the stock trading below key moving averages, and the earnings outlook includes a material reported revenue decline in 2026 driven by divestiture and nonrecurring revenue roll-off, raising execution risk despite positive free-cash-flow commitments.
To see Spark’s full report on XTNT stock, click here.
More about Xtant Medical Holdings
Xtant Medical Holdings, Inc. is a global medical technology company focused on the design, development and commercialization of orthobiologics for chronic and surgical wound care and sports medicine markets, as well as spinal implant systems. The company positions itself as a provider of comprehensive surgical solutions for spinal and other orthopedic conditions through a broad biologics and implant portfolio.
Average Trading Volume: 163,192
Technical Sentiment Signal: Strong Sell
Current Market Cap: $67.23M
For a thorough assessment of XTNT stock, go to TipRanks’ Stock Analysis page.